Bioxcel Therapeutics Inc (BTAI)

Bioxcel Therapeutics (BTAI) Stock Price & Analysis


BTAI Stock Chart & Stats

Day’s Range$0 - $0
52-Week Range$2.23 - $34.13
Previous Close$3.8
Average Volume (3M)3.27M
Market Cap
Enterprise Value$120.90M
Total Cash (Recent Filing)$89.96M
Total Debt (Recent Filing)$99.62M
Price to Earnings (P/E)-0.5
Mar 07, 2024
Next Dividend Ex-DateN/A
Dividend YieldN/A
Share Statistics
EPS (TTM)-7.36
Shares Outstanding29,272,671
10 Day Avg. Volume1,070,327
30 Day Avg. Volume3,274,172
Standard Deviation0.35
Financial Highlights & Ratios
Price to Book (P/B)-2.81
Price to Sales (P/S)467.38
Price to Cash Flow (P/CF)-0.80
P/FCF Ratio0.00
Enterprise Value/Market CapN/A
Enterprise Value/Revenue97.34
Enterprise Value/Gross Profit340.56
Enterprise Value/Ebitda-0.61
Price Target Upside169.92% Upside
Rating ConsensusModerate Buy
Number of Analyst Covering6



Ownership Overview

16.30% Mutual Funds
9.15% Other Institutional Investors
74.55% Public Companies and Individual Investors


What was Bioxcel Therapeutics Inc’s price range in the past 12 months?
Bioxcel Therapeutics Inc lowest stock price was $2.23 and its highest was $34.13 in the past 12 months.
    What is Bioxcel Therapeutics Inc’s market cap?
    Currently, no data Available
    When is Bioxcel Therapeutics Inc’s upcoming earnings report date?
    Bioxcel Therapeutics Inc’s upcoming earnings report date is Mar 07, 2024 which is in 96 days.
      How were Bioxcel Therapeutics Inc’s earnings last quarter?
      Bioxcel Therapeutics Inc released its earnings results on Nov 14, 2023. The company reported -$1.72 earnings per share for the quarter, missing the consensus estimate of -$1.274 by -$0.446.
        Is Bioxcel Therapeutics Inc overvalued?
        According to Wall Street analysts Bioxcel Therapeutics Inc’s price is currently Undervalued. Get more investment ideas with TipRanks Premium
          Does Bioxcel Therapeutics Inc pay dividends?
          Bioxcel Therapeutics Inc does not currently pay dividends.
          What is Bioxcel Therapeutics Inc’s EPS estimate?
          Bioxcel Therapeutics Inc’s EPS estimate is -$0.91.
            How many shares outstanding does Bioxcel Therapeutics Inc have?
            Bioxcel Therapeutics Inc has 29,272,670 shares outstanding.
              What happened to Bioxcel Therapeutics Inc’s price movement after its last earnings report?
              Bioxcel Therapeutics Inc reported an EPS of -$1.72 in its last earnings report, missing expectations of -$1.274. Following the earnings report the stock price went down -23.412%.
                Which hedge fund is a major shareholder of Bioxcel Therapeutics Inc?
                Among the largest hedge funds holding Bioxcel Therapeutics Inc’s share is Driehaus Capital Management LLC. It holds Bioxcel Therapeutics Inc’s shares valued at 56K.


                  Company Description

                  Bioxcel Therapeutics Inc

                  BioXcel Therapeutics, Inc. is a clinical stage biopharmaceutical company focuses on drug development. The firm's two clinical development programs are BXCL501, a sublingual thin film formulation designed for acute treatment of agitation resulting from neurological and psychiatric disorders, and BXCL701, an immuno-oncology agent designed for treatment of a rare form of prostate cancer and for treatment of pancreatic cancer. The company was founded by Vimal D. Mehta on March 29, 2017 and is headquartered in New Haven, CT.


                  Top 5 ETFs holding BTAI

                  Market Value
                  Smart Score
                  Vanguard Total Stock Market ETF
                  Schwab U.S. Broad Market ETF
                  iShares Russell 3000 ETF
                  Vanguard Russell 3000 ETF
                  UBS (Irl) ETF PLC - MSCI USA Select Factor Mix UCITS ETF Accum A Hedged CHF
                  Up to five ETFs with an Outperform Smart Score that hold BTAI. The ETFs are listed according to market value of BTAI within the ETF

                  Forecast EPS vs Actual EPS

                  Similar Stocks
                  Price & Change
                  Arcutis Biotherapeutics
                  Ultragenyx Pharmaceutical
                  Orchard Therapeutics
                  Corbus Pharmaceuticals

                  Popular Stocks

                  What's Included in PREMIUM?
                  Make informed decisions based on Top Analysts' activity
                  Know what industry insiders are buying
                  Get actionable alerts from top Wall Street Analysts
                  Find out before anyone else which stock is going to shoot up
                  Get powerful stock screeners & detailed portfolio analysis